A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs Baricitinib (Primary)
- Indications Primary biliary cirrhosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly and Company
- 19 Oct 2019 Status changed from active, no longer recruiting to completed.
- 28 Aug 2019 Planned End Date changed from 15 Dec 2020 to 26 Sep 2019.
- 28 Aug 2019 Planned primary completion date changed from 20 Jan 2020 to 26 Sep 2019.